We observed that the PBIShi group showed an overall increase in serum inflammatory cytokine levels, including IL-6, suggesting that systemic inflammation itself might contribute to the decreased effect of immunotherapy for HCC. Here, IL6 is linked to hepatocellular carcinoma.